Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

95 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.
Issa JJ, Roboz G, Rizzieri D, Jabbour E, Stock W, O'Connell C, Yee K, Tibes R, Griffiths EA, Walsh K, Daver N, Chung W, Naim S, Taverna P, Oganesian A, Hao Y, Lowder JN, Azab M, Kantarjian H. Issa JJ, et al. Among authors: tibes r. Lancet Oncol. 2015 Sep;16(9):1099-1110. doi: 10.1016/S1470-2045(15)00038-8. Epub 2015 Aug 19. Lancet Oncol. 2015. PMID: 26296954 Free PMC article. Clinical Trial.
Activity of alemtuzumab in patients with CD52-positive acute leukemia.
Tibes R, Keating MJ, Ferrajoli A, Wierda W, Ravandi F, Garcia-Manero G, O'Brien S, Cortes J, Verstovsek S, Browning ML, Faderl S. Tibes R, et al. Cancer. 2006 Jun 15;106(12):2645-51. doi: 10.1002/cncr.21901. Cancer. 2006. PMID: 16688777 Free article. Clinical Trial.
Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
Estey E, de Lima M, Tibes R, Pierce S, Kantarjian H, Champlin R, Giralt S. Estey E, et al. Among authors: tibes r. Blood. 2007 Feb 15;109(4):1395-400. doi: 10.1182/blood-2006-05-021907. Epub 2006 Oct 12. Blood. 2007. PMID: 17038533 Free article. Clinical Trial.
Functional proteomic profiling of AML predicts response and survival.
Kornblau SM, Tibes R, Qiu YH, Chen W, Kantarjian HM, Andreeff M, Coombes KR, Mills GB. Kornblau SM, et al. Among authors: tibes r. Blood. 2009 Jan 1;113(1):154-64. doi: 10.1182/blood-2007-10-119438. Epub 2008 Oct 7. Blood. 2009. PMID: 18840713 Free PMC article.
Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies.
Weiss GJ, Infante JR, Chiorean EG, Borad MJ, Bendell JC, Molina JR, Tibes R, Ramanathan RK, Lewandowski K, Jones SF, Lacouture ME, Langmuir VK, Lee H, Kroll S, Burris HA 3rd. Weiss GJ, et al. Among authors: tibes r. Clin Cancer Res. 2011 May 1;17(9):2997-3004. doi: 10.1158/1078-0432.CCR-10-3425. Epub 2011 Mar 17. Clin Cancer Res. 2011. PMID: 21415214 Clinical Trial.
Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies.
Garcia-Manero G, Tibes R, Kadia T, Kantarjian H, Arellano M, Knight EA, Xiong H, Qin Q, Munasinghe W, Roberts-Rapp L, Ansell P, Albert DH, Oliver B, McKee MD, Ricker JL, Khoury HJ. Garcia-Manero G, et al. Among authors: tibes r. Invest New Drugs. 2015 Aug;33(4):870-80. doi: 10.1007/s10637-015-0242-6. Epub 2015 May 2. Invest New Drugs. 2015. PMID: 25933833 Free PMC article. Clinical Trial.
95 results